Concepedia

Author

Jason J. Luke

University of ChicagoORCID

Also Known As

G Melanoma, Heinrich, Michael C., Igor Puzanov, J J Luke, J Luke, J. J. Luke, J. Luke, J.. Luke, J.J. LUKE, J.J. Luke

804

Publications

22.2K

Citations

63

H-Index

115

Concepts

All Affiliations

University of ChicagoUPMC Hillman Cancer CenterDana-Farber Cancer InstituteThe University of Texas MD Anderson Cancer CenterMemorial Sloan Kettering Cancer Center
JJ

About

Jason J. Luke is an author at University of Chicago specializing in medicine, oncology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

33

70

4.1K

2

Health Sciences

13

13

528

3

Engineering

2

2

69

4

Public Health

1

1

57

5

Allergy

1

1

24

Jason J. Luke

×

168

Publications

17.2K

Citations

56

H-Index

YearCitations

The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

Vyara Matson, Jessica Fessler, Riyue Bao,

Science

2018

2.8K

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

Christophe Massard, Michael S. Gordon, Sunil Sharma,

Journal of Clinical Oncology

2016

839

Noninvasive Detection of Response and Resistance in <i>EGFR</i> -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

Geoffrey R. Oxnard, Cloud P. Paweletz, Yanan Kuang,

Clinical Cancer Research

2014

772

WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers

Jason J. Luke, Riyue Bao, Randy F. Sweis,

Clinical Cancer Research

2019

642

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

Jeffrey S. Weber, Matteo S. Carlino, Adnan Khattak,

The Lancet

2024

598

Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

F. Stephen Hodi, Christopher L. Corless, Anita Giobbie‐Hurder,

Journal of Clinical Oncology

2013

584

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

Jason J. Luke, Jeffrey M. Lemons, Theodore Karrison,

Journal of Clinical Oncology

2018

574

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Lucie Heinzerling, Patrick A. Ott, F. Stephen Hodi,

Journal for ImmunoTherapy of Cancer

2016

503

Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma

Stefani Spranger, Jason J. Luke, Riyue Bao,

Proceedings of the National Academy of Sciences

2016

399

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

Tara C. Mitchell, Omid Hamid, David C. Smith,

Journal of Clinical Oncology

2018

378

Page 1